Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Pharmaceutical Development
Download ReportTranscript Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Pharmaceutical Development
Pharmaceutical Development
Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations
Tallinn 15-19th October 2007
Slide 1 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Pharmaceutical Development Pharmaceutical Development of Finished Pharmaceutical Products (FPPs)
Presenter: Email: Susan Walters [email protected]
Slide 2 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
The Australian view of the world
We are here
!
This place isn’t too bad either
!
Slide 3 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What Australia gave to the world (1)
Slide 4 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What Australia gave to the world (2)
Slide 5 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Pharmaceutical Development of FPPs
Outline of presentation We will:
Look at the development process as a whole & consider its objectives
Review relevant guidelines
Review sources of information
Go through a worked example
Slide 6 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Objectives of Pharmaceutical Development :
What is the purpose?
From the perspective of a generic manufacturer, the objective is to develop a product that is:
of appropriate quality &
interchangeable with the innovator brand (so we can avoid expensive & time-consuming studies of safety & efficacy)
Slide 7 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Objectives of Pharmaceutical Development :
What is the purpose?
From the perspective of the manufacturer of a new dosage form &/or strength (eg a paediatric dosage form), the objective is to develop a product that is: Of appropriate quality, & Of appropriate dosage form & strength, & Either has been shown to be safe & effective for the claimed indications & patient population or has been shown to pharmacokinetically interchangeable with a brand that has been shown to be safe & effective for the claimed indications & patient population However safety & efficacy is outside the scope of this presentation so I will deal only with generics that contain the same API in the same dosage form & strength as the innovator
Slide 8 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Development of a paediatric dosage form
Define drug & dosage regime for the paediatric indication Consider: · Suitable routes of administration · Suitable dosage forms Review literature data &/or conduct own studies Consider pharmacokinetic characteristics of API including: · Half life, Cmax, AUC · BCS classification if oral route is intended Determine & prepare for studies likely to be required relating to BABE Determine: · Relevant physicochemical · · characteristics of API Stability of API under stress conditions Compatibility of API with common excipients Select a dosage form & strength Sources of possible formulations & manufacturing procedures: · Innovator excipients · Your company’s prior experience · Commercially available formulations & manufacturing procedures · WHO ‘starting-point’ formulations Consider suitable, formulations & manufacturing procedures Prepare early batches & test relevant characteristics including: · Dissolution rate · Stability · Pilot BE study if necessary Define design space Apply optimization techniques/validate formulation & method of manufacture Decide final formulation, method of manufacture & packaging Conduct: · Confirmatory stability studies · Confirmatory dissolution studies · Final BE study if needed Submit application for prequalification
Slide 9 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Review literature data &/or conduct own studies Prepare draft prescribing information Finalise prescribing information
Product & process development
(sorry don’t know the source of this diagram) Key elements Facilities
and
Equipment Preparatory phase
(
Validation
of
analytical methods
)
Slide 10
(
Qualification
Stage Design & C Installation Engineering phase
Validation
Protocols) Operation
Validation
Prospective Manufacturing Start-Up (Batch Records and
Validation Design (laboratory)
(
Critical attributes
and
formula screening
)
Scale-Up (pilot plant)
(
process optimization
and
stability batch biobatch
)
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Stage Concurrent documentation)
Production
(
final batch size
,
reproducible quality
)
CONTINUOUS IMPROVEMENT
Terminology –
from ICH Q1A(R2) 2003 (stability)
Slide 11
-
Production batch:
– A batch of a drug substance or drug product manufactured at production scale by using production equipment in a production facility as specified -
Pilot scale batch:
– A batch of a drug substance or drug product manufactured by a procedure fully representative of and simulating that to be applied to a full production scale batch. For solid oral dosage forms, a pilot scale is generally, at a minimum, one tenth that of a full production scale or 100,000 tablets or capsules, whichever is the larger.
-
Laboratory scale batch
[not an ICH definition] A batch smaller than pilot scale that is manufactured for development purposes Remember that scale-ups must be validated – batch characteristics may change during scale-up
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Relevant non-WHO guidelines
Slide 12
ICH Q8
Pharmaceutical Development
(2005)
ICH Q9
Quality Risk Management
(Nov 2005)
ICH Q10 DRAFT
Pharmaceutical Quality System
(May 2007)
Note for guidance on Process Validation
CHMP/QWP/848/96 (EU 2001) – An elderly guideline but informative & helpful
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Relevant WHO guidelines
Pharmaceutical Development,
Section 3.2 of Guideline on Submission of Documentation for Prequalification of Multi source (Generic) Finished Pharmaceutical Products (FPPs) Used in the Treatment of HIV/AIDS, Malaria and Tuberculosis , WHO PQP (2005)
Extension of the WHO List of Stable (not easily degradable ARV) APIs,
Supplement 2 (Rev 1) to Guideline on Submission of Documentation for Prequalification of Multi-source (Generic) Finished Pharmaceutical Products (FPPs) Used in the Treatment of HIV/AIDS, Malaria and Tuberculosis , WHO PQP (2005)
Supplementary guidelines on Good Manufacturing Practices: Validation,
Annex 4 to WHO TRS 937 (2006)
Slide 13 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Some relevant journals
Pharmaceutical Technology Pharmaceutical Technology Europe Pharmaceutical Industry Pharmaceutical Development and Technology Drug Development & Industrial Pharmacy Pharmaceutical Manufacturing Dissolution Technologies European Journal of Pharmaceutics and Biopharmaceutics Pharmazie in Unserer Zeit S.T.P. Pharma Pratiques
- A free on-line journal at (often in French)
Pharmaceutisch Weekblad
(often in German) (often in German) http://www.dissolutiontech.com/
It is often possible to obtain access to journals via university on-line databases Slide 14 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Some relevant websites
Slide 15
http://www.who.int/medicines/en/ .
–
WHO medicines program.
http://mednet3.who.int/prequal/
–
WHO prequalification program.
http://www.ich.org
–
ICH website
http://www.emea.europa.eu/htms/human/humanguidelines/background.
htm
–
European guidelines for human medicines
http://www.fip.org/www2/sciences/index.php
–
international Pharmaceutical Federation: Pharmaceutical Sciences section
http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm
–
Dissolution methods for drug products Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
How can we optimise the possibility of developing an acceptable product? - 1
Form a development team – Include staff with experience in formulation, manufacturing, quality control, stability testing Prepare a development plan, set goals & timelines, & monitor progress with regular meetings (eg weekly in the first instance) Make use of experienced staff within your company, especially in relation to manufacturing equipment & procedures Review the literature for information on: – – Chemical & physicochemical properties of the API(s) Information on the innovator product Conduct experiments to fill in the gaps in information, – Especially concerning API properties & compatibilities If possible, use the same excipients as the innovator. – Less likely to encounter problems with compatibility, stability, bioequivalence If possible, use standard manufacturing procedures with which your company has experience – More likely to achieve suitable dissolution properties & reproducible manufacturing
Slide 16 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
How can we optimise the possibility of developing an acceptable product? - 2
BOTTOM LINE: – Ensure our product meets WHO criteria for quality, stability & – interchangeability Ensure our product has similar dissolution characteristics as the innovator at various pH – May need to confirm bioequivalence with the innovator • See Annex 8 to WHO TRS 937 (2006) Proposal to waive in vivo
bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms
Slide 17 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What are the chemical & physicochemical properties of API(s) that we need to know, or are at least useful?
Solubility at various pH
Acid or base?
pKa & partition coefficient
Stability under stress (eg oxygen, moisture, acid etc)
Compatibility with common excipients
Slide 18 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What literature should we look for?
Look for …… A WHOPAR, if one is available for your product – See http://mednet3.who.int/prequal/default.htm
Quick Links
on the RH side of the page . Look for
WHO Public Assessment Reports
under Innovator documentation. – – Can often be found on the innovator website. The prescribing information is especially useful & often includes a list of excipients.
A drug approval package (DAP) via An EPAR ( http://www.fda.gov/cder/foi/nda/
European Public Assessment Report
) An official monograph in the (latest edition 2004).
Ph Int
A monograph in
Clarke ’s Analysis of Drugs and Poisons
, published by The Pharmaceutical Press A monograph in
The Merck Index
Regulatory information – , published by CambridgeSoft (latest edition 2001). See for example the WHO information line [email protected]
.
Slide 19 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Case study: A new brand of Nevirapine 50mg/5 ml oral suspension - 1
Slide 20
Why do we need to know the chemical structure?
To determine whether the active is an acid, base or neutral To assist in devising assay procedures To determine likely compatibilities/incompatibilities – Based on a knowledge of organic chemistry To inform other decisions & predictions that are based on chemistry
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Case study: A new brand of Nevirapine 50mg/5 ml oral suspension - 2
We plan to develop a paediatric product that contains the same active in the same dose & dosage form as an existing paediatric product. The innovator is Boehringer Ingelheim. The innovator brand name is
Viramune®
50 mg/5mL oral suspension. The product under development is a multisource (generic) product. The quality, safety & efficacy of the existing product have been established. The product will be an oral suspension containing 50mg of nevirapine in each 5mL. The drug is present as an equivalent quantity of the hemihydrate API. – Note that the API is often a salt or solvate of the active ingredient. In this case the API is the hemihydrate of nevirapine.
Slide 21 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What useful sources of information did we find?
An EPAR at http://www.emea.europa.eu/humandocs/PDFs/EPAR/Viramune/109697en6.pdf
A drug approval package (DAP) at http://www.fda.gov/cder/foi/nda/98/20 933_20-636S009_Viramune.htm
A letter of approval at
http://www.fda.gov/cder/ogd/rld/20933s3.PDF
An official monograph in the Ph Int.
A monograph in Clarke’s Analysis of Drugs and Poisons, published by The Pharmaceutical Press 2004.
A monograph in The Merck Index, published by CambridgeSoft 2001.
Regulatory information concerning a possible impurity in the API. See http://www.medicalnewstoday.com/articles/82050.php
Slide 22 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What useful information did we find? - 1
Nevirapine is lipophilic (partition coefficient 83) & is essentially nonionized at physiological pH As a weak base (pK a 2.8), nevirapine shows increased solubility at acidic pH The aqueous solubility (of the anhydrate) is 90μg/ml at 25 ° C Nevirapine is generally stable when stressed
Slide 23 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What useful information did we find? - 2
There are two crystal forms of the API No polymorphic changes were observed under stressed conditions The API (hemihydrate) is non-hygroscopic The synthesis of the two crystal forms is similar until the final drying step The impurity profile is well characterised Impurities arising from the synthesis have been toxicologically qualified No degradation products were detected during stability testing of the API The API is milled in order to obtain an acceptable particle size distribution for the suspension Nevirapine is official in the
Ph Int
Batch analysis data confirmed that nevirapine hemihydrate complies with the specifications
Slide 24 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What useful information did we find? - 3
The innovator markets an oral suspension ( Viramune ® 50 mg/5 ml) containing nevirapine (present as the hemihydrate at 10.35 mg/ml).
– That is….the active is nevirapine & the API is nevirapine hemihydrate Excipients in the innovator formulation are: – Carbomer 934P (synthetic high molecular weight crosslinked polymers of acrylic acid), methyl & propyl hydroxybenzoates, sorbitol, sucrose, polysorbate 80, NaOH, purified water. The shelf life of the innovator is 3 years. – The product should be used within 2 months of opening (‘in-use’ stqbility).
The innovator has no special precautions for storage
Slide 25 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What useful information did we find? - 4
The innovator’s container is a white HDPE bottle with two piece child-resistant closure (outer shell white HDPE, inner shell natural polypropylene) with LDPE foam liner. Each bottle contains 240 ml of oral suspension.
Included with the innovator product is a clear polypropylene 5-ml dispensing syringe (0.2 ml graduations) with silicone rubber piston seal, & a clear low density polyethylene bottle-syringe adapter.
See http://www.emea.europa.eu/humandocs/PDFs/EPAR/Viramune/109697en6.pdf
http://www.fda.gov/cder/ogd/rld/20933s3.PDF
A monograph (
Ph Int
) is being developed for the FPP, nevirapine oral suspension – NB check the WHO website for the latest information
Slide 26 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What useful information did we find? - 5
The HDPE bottle is inert & has been shown to be compatible with the active substance & other ingredients of the innovator’s formulation.
% content of antimicrobial preservatives has been correlated with antimicrobial effectiveness when tested according to
Ph Eur
methodology Acceptable data are available to demonstrate the precision & accuracy of the innovator’s dosing syringe None of the synthesis impurities are degradants The method of preparation of the oral suspension is standard for this dosage form & has been well described. Validation data presented for three production batches manufactured using three different lots of nevirapine demonstrated that the process is under control & ensures both batch-to-batch reproducibility & compliance with standard specifications. Tests at release are typical & ensure reproducible performance of the product.
Slide 27 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What useful information did we find? - 6
Stability data are available for up to 18 months for the innovator. Long-term stability data have been promised on an ongoing basis.
An in-use stability study has been performed that mimics delivery of a 2mL dose, representing one of the lowest projected doses using the delivery device intended for marketing An additional study has been conducted on the stability of the product exposed to freeze-thaw conditions On the basis of results from these studies, an in-use shelf life of 60 days with no special storage precautions is claimed
Slide 28 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What useful information did we find? – 7
In vivo
data provided by the innovator included the following : Nevirapine is readily absorbed (> 90 %) after oral administration in healthy volunteers & in adults with HIV-1 infection.
A 3-way crossover study comparing the bioavailability of three production/commercial scale batches that had varying dissolution profiles showed that all three batches were bioequivalent with respect to systemic exposure (AUC). The statistically significantly different values for Cmax and tmax were considered not to be clinically relevant.
In studies in which the suspension was administered directly using a syringe, it was demonstrated that the suspension & tablet formulations were comparably bioavailable with respect to extent of absorption. In a study in which the suspension was administered in a dosing cup without rinsing, the suspension intended for marketing was bioequivalent to the suspension used during clinical trials but was not bioequivalent to the marketed tablets. This was attributed to incomplete dosing of the two suspensions since there was about 13 % of the dose remaining in the cup.
Slide 29 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
What useful information did we find? – 8
Based on adult experience, a comparable lead-in period of two weeks was suggested for paediatric population. A 4 mg/kg dose is proposed for all children regardless of age. Although no particular study has been performed to find the optimal lead-in dose, this dose was considered acceptable considering the enzyme induction to achieve initial antiretroviral activity.
The following doses were approved: – Patients from 2 months to 8 years, 4mg/kg once daily for 2 weeks followed by 7mg/kg twice daily – Patients from 8 years to 16 years, 4 mg/kg once daily followed by 4mg/kg twice daily
Slide 30 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Benchmarking the innovator – 1
(these slides were taken from a presentation by János Pogány )
Obtain a sample for confirmation of characteristics – – – – Batch numbers Shelf life: 3 years and within 2 months of opening .
Storage instructions: No special precautions for storage Container and closure system: as per EPAR QC analysis – – – – – – – Assay: 99.9% of labelled amount (LA) Methylhydroxy benzoate (HPLC): 0.18% w/v Propylhydroxy benzoate (HPLC): 0.02% w/v Total related substances: 0.03% Specific gravity (at 25 o C): 1.150 Viscosity (at 25 o C): 1,150 cPs pH: 5.80
(hypothetical figures)
Slide 31 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Benchmarking the innovator - 2
The qualitative composition suggests that: Sucrose and sorbitol are used to adjust the density of the medium Carbomer 934P is used to adjust viscosity Polysorbate is a wetting agent Sodium hydroxide is used to adjust the pH to 5.8
Slide 32 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Slide 33
Benchmarking the innovator – 3 Our tests show…..
Time (minutes) 5 10 15 20 30 45 60 % API dissolved (hypothetical figures) 27 42 Dissolution profile (% labeled strength) Apparatus: USP II (paddle, 25rpm) 55 Medium: 0.1N HCl 65 Volume: 900ml 76 88 See http://www.accessdata.fda.gov/scripts/cder/diss olution/dsp_SearchResults_Dissolutions.cfm
downloaded on 13 March 2007 92
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Benchmarking the innovator - 4 Our tests show…..
% API dissolved
(hypothetical figures)
% API dissolved
(hypothetical figures)
% API dissolved
(hypothetical figures)
Time (minutes) 5 10 15 20 30 45 60 pH 1.2 buffer 27 42 55 65 76 88 92 pH 4.5 buffer 15 25 36 42 48 49 49 pH 6.8 buffer 22 27 35 42 49 57 65 90 100 50 76 Dissolution profile (% LA), Apparatus: USP II (paddle, 25rpm), Volume: 900ml – Different speeds to be investigated
Slide 34 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Pharmaceutical development protocol
API experiments – Particle size distribution Formulation experiments – Screening laboratory batches with different proportions of excipients to match innovator dissolution – – – Stress testing of the selected composition Compatibility with excipients Antimicrobial effectiveness test according to
Ph Eur
Packing materials – – Dimensions and tolerances of packing components Precision & accuracy of the dosing syringe
Slide 35 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Product-specific API properties
Ph Int specifications + limits on residual solvents from API manufacture Product-specific physical properties depend on crystallization and subsequent physical processing. Density and particle size distribution of nevirapine hemihydrate are critical quality attributes. Acceptance criteria are established by measurement of particle size of innovator’s API in suspension & through the similarity of dissolution profiles of innovator and generic products.
Slide 36 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Slide 37
Undertake stress testing of the API
if not already available in existing documentation
Stress type Control 36% HCl 5N NaOH 30% w/w H 2 O 2 Heat Light Water Conditions 25 o C 80o C, 40 min.
80 o C, 2h 20 ’ 80 o C, 2h 20 ’ 130 o C, 49h 500W/m 2 , 68h 25 o C, 92% RH, 91h Assay (%) 99.8
72.0
98.6
98.6
101.5
101.7
101.2
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Solubility of nevirapine hemihydrate at 37
o
C
If not already available in existing documentation
(
hypothetical figures)
8.0
0.06
Note: Nevirapine hemihydrate belongs to BCS2 (low solubility, high permeability) – See Annex 8 to WHO TRS 937 (2006) Solubility data are also important for cleaning validation
Slide 38 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Dissolution profiles of innovator & generic FPPs Hypothetical data Slide 39 M e a n % A P I l v e d d i s s o
120 100 80 60 40 20 0 0 10 20 30 40 50
Time (minutes) Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
60 70 80 90
▀ innovator ▀ generic Similarity factor f 2 =73
Selected generic composition
Hypothetical numbers
Ingredients
Nevirapine hemihydrate
mg/5ml 51.7
Excipients
– Carbomer 934P – – – – Methyl parahydroxybenzoate Propyl parahydroxybenzoate Sorbitol Sucrose (!) – – – Polysorbate 80 Sodium hydroxide Purified water to make 7.0
9.0 0.9
900.0
500.0
4.0
q.s.
5.0 ml
Slide 40 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Proposed FPP specifications
A hypothetical set of limits
Description: including at least colour, texture, odour Identification (HPLC) Dissolution (UV): Q = 70% in 45 minutes pH = 5.0
– 6.1
Deliverable volume – – – – Average fill volume: NLT 240 ml Fill volume variation: Meets Ph Int requirements Related substances: NMT 0.1% of any one imp & NMT 0.3% total imps Preservative content (HPLC) Methylparaben: 98 to 102% of labeled strength Propylparaben: 98 to 102% of labeled strength Assay: 95.0 to 105.0% of labeled strength
Slide 41 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Compatibility with excipients
May not need to do this if use only the same excipients as the innovator
Nevirapine hemihydrate in solid state – illustrative example: heat Stress Condition None Heat Treatment Initial values API API is mixed with excipient, the mixture is wetted and a thin layer of the powder blend is kept at 60°C for 4 weeks in a Petri dish (open system) Observations Assay: Impurity 1: Impurity 2: Total unspecified imps: Total impurities: Assay: Impurity 1: Impurity 2: Total unspecified imps: Total impurities:
Slide 42 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Development of manufacturing process
Select a standard process for oral aqueous suspensions, if possible using our existing method Manufacture a lab scale batch – If necessary make adjustments & manufacture another lab scale batch When satisfied with the formulation, manufacture a pilot scale batch – – If necessary make adjustments & manufacture another pilot scale batch Recollect that a pilot batch is manufactured by a procedure fully representative of and simulating that to be applied to a full production scale batch Manufacture primary* batches in the proposed container & closure systems for: – Bioequivalence & dissolution studies – Regulatory stability studies • Iincluding an in-use stability study & a stress study under freeze-thaw conditions – Validation of bioequivalence, dissolution & stability batches *
Primary
as defined in WHO/ICH guidelines
Slide 43 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Development of manufacturing process
Note that the progress from pre-formulation to formulation to pilot manufacture to production scale manufacture should be described in the PQP dossier & shown to be logical, reasoned & continuous
Slide 44 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Scale up activities
Test a large number of samples from pilot scale batches to establish provisional acceptance limits for the control of critical process parameters (prospective validation, in-process control limits) in order to define the design space* & a control strategy that encompasses batch scale, equipment, packaging, as well as final product stability. The process will be well understood when: – – – all critical sources of variability have been identified & explained variability is managed by the process product quality attributes can be accurately & reliably predicted A validation protocol is written * See ICH Q8, Q9 & draft Q10 for further explanation
Slide 45 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Dissolution & bioequivalence testing
Innovator FPP
Conduct a dissolution test on at least 3 batches Select a batch showing intermediate dissolution Reference product
Generic FPP
Select a production batch, or one NLT 1/10 th of final size Test product Dissolution profile Bioequivalence study
Slide 46 Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007
Pharmaceutical Development
Summary and conclusion
The probability of producing a product that is:
-
Of high quality
-
Stable
-
Consistent from batch to batch, &
-
Bioequivalent to the innovator Slide 47 can be significantly improved by employing a planned & systematic approach to product development, & using all the information that has been published Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines 15-19 October 2007